Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.22 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.
Chugai Pharmaceutical Stock Performance
OTCMKTS:CHGCY traded down $0.06 during mid-day trading on Friday, hitting $22.05. 176,107 shares of the stock were exchanged, compared to its average volume of 242,348. The firm’s 50-day simple moving average is $23.46 and its 200 day simple moving average is $26.43. The stock has a market capitalization of $72.58 billion, a price-to-earnings ratio of 24.50 and a beta of 0.59. Chugai Pharmaceutical has a fifty-two week low of $19.50 and a fifty-two week high of $34.84.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on CHGCY shares. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Chugai Pharmaceutical has a consensus rating of “Buy”.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Featured Stories
- Five stocks we like better than Chugai Pharmaceutical
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
-pt-telekomunikasi-indonesia-tbk-logo-1200x675.png){kind=logo}
